Active, not recruitingPhase 3NCT04895241
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
Studying Autosomal systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Biogen
- Principal Investigator
- Medical DirectorBiogen
- Intervention
- Litifilimab(drug)
- Enrollment
- 548 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (30)
- Tilda Research Birmingham, Homewood, Alabama, United States
- Wallace Rheumatic Study Center, Beverly Hills, California, United States
- University of Southern California, Los Angeles, California, United States
- Providence Facey Medical Foundation, Mission Hills, California, United States
- University of California San Diego School of Medicine, San Diego, California, United States
- SCLA Management, Thousand Oaks, California, United States
- Harbor-UCLA Medical Center, Torrance, California, United States
- Inland Rheumatology Clinical Trials, Inc., Upland, California, United States
- University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- Georgetown University Hospital-Medstar, Washington D.C., District of Columbia, United States
- Arthritis & Rheumatic Disease Specialties, Aventura, Florida, United States
- Highlands Rheumatology, Avon Park, Florida, United States
- Clinical Research of West Florida - Corporate, Clearwater, Florida, United States
- Believe Clinical Trials, Coral Springs, Florida, United States
- Omega Research Consultants, DeBary, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04895241 on ClinicalTrials.govOther trials for Autosomal systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07447986To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus ErythematosusHangzhou Sumgen Biotech Co., Ltd.
- RECRUITINGPHASE1NCT07363590A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)Merck Sharp & Dohme LLC
- RECRUITINGPHASE3NCT07201129A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular TreatmentViatris Innovation GmbH
- RECRUITINGPHASE1NCT07276958A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)Eli Lilly and Company
- RECRUITINGPHASE1, PHASE2NCT07348055A Study of GR1803 in Systemic Lupus ErythematosusGenrix (Shanghai) Biopharmaceutical Co., Ltd.
- RECRUITINGPHASE1NCT07318259Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLEChongqing Precision Biotech Co., Ltd
- RECRUITINGNCT07000110Anifrolumab Malignancy and Serious Infections StudyAstraZeneca
- RECRUITINGPHASE1NCT07331467Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLEChongqing Precision Biotech Co., Ltd